Immune checkpoint inhibitor co-expression vectors

A carrier system, immune regulation technology, applied in the direction of immunoglobulin, introduction of foreign genetic material using carrier, vaccine, etc.

Pending Publication Date: 2021-02-09
GRITSTONE BIO INC
View PDF27 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] In addition to the challenges of current neoantigen prediction methods, there are certain challenge

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Immune checkpoint inhibitor co-expression vectors
  • Immune checkpoint inhibitor co-expression vectors
  • Immune checkpoint inhibitor co-expression vectors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0142] I. Definition

[0143] Generally, the terms used in the claims and specification are intended to be interpreted to have their ordinary meanings as understood by those of ordinary skill in the art. For clarity, certain terms are defined below. In the event of a conflict between the ordinary meaning and the provided definition, the provided definition shall apply.

[0144] As used herein, the term "antigen" is a substance that induces an immune response. An antigen can be a neoantigen. Antigens may be "consensus antigens," which are antigens found in a particular population (eg, a particular population of cancer patients).

[0145] As used herein, the term "neoantigen" is an antigen that has at least one alteration that makes it different from the corresponding wild-type antigen, for example via a mutation in a tumor cell or a post-translational modification specific for a tumor cell. Neoantigens can include polypeptide sequences or nucleotide sequences. Mutations ma...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Disclosed herein are vectors that include antigen-encoding nucleic acid sequences and co-express immune modulators. Also disclosed are nucleotides, cells, and methods associated with the vectors including their use as vaccines.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of U.S. Provisional Application No. 62 / 675,624, filed May 23, 2018, which is hereby incorporated by reference in its entirety for all purposes. [0003] sequence listing [0004] This application contains a Sequence Listing, which has been filed electronically in ASCII format, and is hereby incorporated by reference in its entirety. Said ASCII copy, created on May 22, 2019, is named GSO_018_WO_Sequence_Listing.txt and is 422,185 bytes in size. Background technique [0005] Therapeutic vaccines based on tumor-specific antigens hold great promise as a new generation of personalized cancer immunotherapy. 1–3 For example, cancers with high mutational burdens, such as non-small cell lung cancer (NSCLC) and melanoma, are particularly attractive targets for such therapies given the relatively high likelihood of neoantigen production. 4,5 Early evidence suggests that neoantigen-based vaccin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/00C12N15/85
CPCA61K39/12C12N2740/14034C12N2710/16134C12N2710/16234C12N2760/16134C12N2730/10134C12N2770/24234A61K2039/70A61K2039/6037A61K2039/605A61K2039/572A61K2039/575C12N2740/16334C12N2710/20034A61K39/001191A61K39/001188A61K2039/6031C12N2710/10343C12N2740/16134C12N2740/16234C12N2770/36143A61P35/00C07K14/70539C07K14/70596C07K14/705C12N15/86C07K16/2818C12Q1/6827A61P31/16A61P31/20C12N2770/24143A61K2039/505A61K39/0012
Inventor W·布莱尔K·朱斯L·吉特林C·D·斯卡伦A·R·拉帕波特G·M·格罗滕布雷格
Owner GRITSTONE BIO INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap